Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I bought six patches in March. My next purchase will take me to 10. So 10 is a low, yet safe, operating assumption to highlight market potential. I also bought the oil.
I plan on being a repeat customer and am very curious about their upcoming new product announcements, and distribution plans.
Here is a link to a 2015 NIH article on chronic pain that estimates 50 million adult Americans live with it.
http://americanpainsociety.org/about-us/press-room/nih-study-shows-prevalence-of-chronic-or-severe-pain-in-u-s-adults
People call the USPTO for information. In this case, we have an unusual situation where one patent-pending invention has two separate published Application Numbers.
Shareholders have been led to believe that Otiko has a transdermal delivery system he can attempt to patent. Some have suggested he has a right to the Keough/Phillips delivery system because the number assigned to one of two published applications has been abandoned.
It was a worthwhile call because it confirmed an existing conflict.
I have called in the past for explanation of a patent status. In that case, I was given info because there was no confidential action underway. So, yes information is shared by this public office when legal challenges don't exist.
I stickied my post regarding the Patent issue. There is a link within the message to the Global Dossier for all affiliated numbers. I noticed prior efforts to link Final status of the Patent App number used by Phillips/Otiko led to dead space. If you use the Dossier link, then click on the number you referenced, you can see the status.
To summarize, this invention is active under the number used by competitor Keough. Otiko cannot claim this invention as his work.
What do you mean by "FDA Approval"? These are Phillips Company products, right? Phillips said no licenses were issued for TetraStem in a recent email with a shareholder. He said ViaDerma has a non-exclusive license to manufacture and distribute Viabecline.
The patent-pending technology is in the name of Phillips/Keough, not Otiko or ViaDerma.
Why would a pharma biz be interested in ViaDerma? Can you elaborate on any assets they may own? Any IP? Revenues or market share they would want to obtain?
I called the USPTO. I referenced Application Serial #13/066,705 attached to Published Application US 2012-0070390 A1 - TOPICAL DRUG DELIVERY SYSTEM WITH DUAL CARRIERS.
There is no Final Action with this Published Application. The last Transaction is dated November 15, 2016. An Information Disclosure Statement is being considered.
The gentleman was very kind and unable to provide information beyond what we see in the Pair database. He did say he didn't want to get in the middle of a dispute and could not discuss anything with shareholders--only the patent inventors.
He suggested calling the Attorney. I gave him the name of David Resnick which is at the top of the list on the Attorney/Agent tab in the database. He confirmed this is the proper contact and gave me his phone number as 617-345-6057. I won't be calling him.
David S. Resnick
Nixon Peabody LLP
100 Summer Street
Boston MA 02110-2131
Here is a link to the Global Dossier associated with these numbers.
https://globaldossier.uspto.gov/#/result/application/US/13066705/652288
I placed patent information in my section of the iBox for a reason--so newcomers don't have to cycle through historical messages to get up to speed.
What is clear is that Phillips/Otiko and Keough use two different Patent-Pending Application Numbers for the same invention. This is the dispute.
Keough has Trademarked Site Specific Penetration Technology for this invention. If you search on this term in Justia, you will see a link to this published patent application. Dakota Life Sciences has an R&D pipeline and products soon to hit the market. They are direct competition to vdrm and probably have much more to offer.
http://dakotalifesci.com
Keough has stated his intention to protect their IP. That message is also linked in the iBox and below. Pharmacline was the Applicant. They are aka Thru Pharma and Dakota Life Sciences. Dakota has merged with Kasten OTC:PK KAST
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129232062
Otiko cannot submit a non-provisional application for this invention and expect it to be published. It's on him to prove he is designing something completely different and has no interest in future litigation.
Apparently, the CEO had a piece of dirt land on him a few years ago while meeting with investors in NY on behalf of his finance business Keystone. This was 100% unrelated to CGRA. I doubt the CEO knew this guy had a rough background.
The Radcliffe boys operate out of a rundown office in upstate New York.
6061 Main Street, Tannersville, NY
They are in the links below and others if you really want to dig around.
https://www.sec.gov/litigation/litreleases/2011/lr21814.htm
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114375202
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128424262
Kenneth Radcliffe filed a RICO claim on Wright/Keystone last December and is suggesting his money went to CGRA. He got hit with a big fine last fall, and needed to come up with six figures quickly. So he has a motive to file a bogus claim and hope it sticks. I've seen this before on another stock. No idea what really happened back then between Keystone and Radcliffe.
https://www.pacermonitor.com/case/20104150/Radcliffe_et_al_v_Wright_et_al
The CEO has a very skilled attorney--link below. They are filing a Motion to Dismiss and going through the Motions and requirements of the court to engage in a settlement conference.
https://www.linkedin.com/in/daniel-s-steinberg-46162576
I'm not concerned. I believe the Motion to Dismiss will be granted.
Been a long investor with many others for awhile.
Those are some nasty rumors. I'm not surprised to see them. None of them are true. The iBox is full of info from 2015-2016.
The company has auditors reviewing their financials. The annual report will be available by April 14.
Their bond company funds the oil and gas operations. The lessors fund the cannabis build out.
The CEO has a finance business known as Keystone. They are registered in WA State.
Could be documentation from Distributor #1--Otiko himself.
:)
What could VDRM be missing that they're going to retrieve in 15 days? Any idea(s)?
Notification of Late Filing
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=168522
The SEC is not an auditor. This could explain why OWCP hires an independent auditor to audit their 10-Ks that they submit to the SEC as a fully reporting OTCQB business.
My message was clear and contained links anyone can use. Google the name of the emerging fund for names of companies. Here is a more comprehensive link.
https://www.newcannabisventures.com/first-cannabis-etf-in-the-works-emerging-agrosphere
Their profile indicates they are audited.
http://www.otcmarkets.com/stock/OWCP/profile
Below is an excerpt from their last 10-K/A.
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES Back to Table of Contents
The Registrant's Board of Directors has appointed M&K CPAS, PLLC ("MK") as independent public accountant for the fiscal year ended December 31, 2015 and 2014.
Principal Accounting Fees
The following table presents the fees for professional audit services rendered by MK for the audit of the Registrant's annual financial statements for the years ended December 31, 2015 and 2014, and fees billed for other services rendered by MK during those periods.
Year Ended Year Ended
December 31, 2015 December 31, 2014
Audit fees (1)
$ 9,250 $ 9,250
Audit-related fees (2)
--- ---
Tax fees (3)
--- ---
All other fees
--- ---
(1) Audit fees consist of audit and review services, consents and review of documents filed with the SEC.
(2) Audit-related fees consist of assistance and discussion concerning financial accounting and reporting standards and other accounting issues.
(3) Tax fees consist of preparation of federal and state tax returns, review of quarterly estimated tax payments, and consultation concerning tax compliance issues.
I'm not confusing anything. Otiko was born and raised in Nigeria. He spent time in London.
The word scam is meaningless to me.
Positive test results were conveyed this month. I doubt they're misleading anyone on that topic. The cream is on the market Q2.
They didn't suggest they were in the Canada ETF. Here's the link to their FB page. They consistently post industry news of interest to cannabis followers.
https://www.facebook.com/OWCpharma
They are named in the pending U.S. ETF linked below.
http://www.businessinsider.com/first-marijuana-etf-2017-2
Finally, they are an audited SEC reporting business that trades on the OTCQB tier.
http://www.otcmarkets.com/stock/OWCP/filings
I have the same high expectations they do. I see a business that can easily reach and maintain NASDAQ price requirements this year. Whether the NASDAQ is in their business plans in 2017 is unknown to me.
I'm here because they are targeting and fulfilling unmet needs of people with difficult medical conditions, AND they have the highest levels of expertise needed to accomplish their goals.
Notifications of Late Filing allow a 15 day extension. This notice clearly states April 14 as the due date.
Looking forward to the 2016 wrap up and the good news coming our way. Revs will be up and will set a new baseline.
No, it is not true. ViaDerma has nothing to offer any pharma or biotechnology biz. The One World rumor is one of the most absurd ones I have seen in penny land.
ViaDerma operates under a non-exclusive license agreement with the Phillips Company out of Oklahoma. Otiko pays Phillips fees and costs associated with manufacturing Viabecline at their facility. It is not clear what else he sells out of his Coast to Coast Clinic in Reseda.
Phillips Company can be acquired. In this case, Otiko stands to lose his non-exclusive license to distribute the Phillips Company products mentioned here.
Otiko is a foot and ankle doctor. His undergrad degree is from a school in Nigeria. Post grad is Oklahoma. Podiatry license is from a school in California.
Same feed as financial reports as well as their filings page.
You can see that other companies file the Notification of Late Filing and read them as examples.
The upload will appear on the feed linked below, their filings page, as well as profile page, IF they are compliant.
http://www.otcmarkets.com/news/otc-financials
Yes, as in tomorrow. They can also upload a Notification of Late Filing and receive a 15 day extension.
Here is the link to the OTC news and report feed.
http://www.otcmarkets.com/news/otc-financials
Premier trades on OTCQB so Level 2 is free thru OTC Markets.
http://www.otcmarkets.com/stock/BIEI/quote
You can also get E*Trade Pro by executing 30 trades per quarter, in lieu of account minimum dollars. Even if you don't hit that quota, once you install it, they won't take it away. Been using it for years. Love it.
They cut their trade fees in half recently, too.
I think there may be a misunderstanding as I don't see ratings.
I'll add the link again below. OTC Markets is the authority. ViaDerma chose the Pink - Current trade tier.
https://www.otcmarkets.com/marketplaces/otc-pink
They use the Alternative Reporting Standard, explained in link below
https://www.otcmarkets.com/learn/otc-company-reporting
I included a link to Pink Sheet info. Read that to better understand OTC market guidelines.
The reports are uploaded and visible on the other link I provided.
The Annual Report is due 90 days after year end.
http://www.otcmarkets.com/stock/VDRM/filings
https://www.otcmarkets.com/marketplaces/otc-pink
Seven pro-marijuana industry bills were announced Thursday morning by a bipartisan group of U.S. lawmakers in the House and Senate, suggesting that 2017 may be the year real reform gets through the Capitol.
https://mjbizdaily.com/seven-pro-cannabis-bills-introduced-thursday-congress/
CGRA can acquire it's tenant Wildfire upon national legalization.
Yep, and it's the FIRST TIME we've seen that reason. A quick review of prior late notices will show that accountants and lawyers needed more time.
Now it's an outside CPA.
Notice of Late Filing
Outside CPA and accountants still reviewing financials. Will file by April 14.
I never separated those thoughts. They do work hand-in-hand. It's like 1 + 1 = 2. Provisional Application + Patent Application = PTO consideration and potential protection.
Why assume he will ever have a published application in his name? Of course, he can submit "his" art to the PTO. Does that mean it will become a published application? Nope.
I believe Otiko is trying to capitalize on the transdermal technology defined in the Phillips/Keough patent (linked in the iBox) and that any effort to obtain a patent stands a high chance of rejection. His word choices match the Phillips/Keough technology. He does nothing to explain the duplicate term, or attempt to define his method as unique.
His false copyright document for the horror flick added to an existing concern.
I also think he may have gone public to fund his personal life. His board of directors consists of himself, his wife and brother.
He failed at novels, movies, and restoration of his character after his Federal case involving prescription drug fraud was plastered across the news, including a podiatry news site. While he was acquitted, his own words commented on the loss of important contacts.
He hasn't shown sources of wealth that would counter my concern. One can say doctors make great money. This doctor, though, operates out of a hell hole of a building.
The Coast to Coast news release I presented previously indicates he revealed a new distributor and didn't let his readers know he IS the distributor.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129838164
I will continue to doubt and examine the pros and cons of this ticker. My instincts have always served me well. I don't trade on TA alone. I always ensure the fundamentals are mostly sound before I take a long position.
I think I addressed this weeks ago. I can't control positive/negative interpretation, am not a paid pumper or basher. I have never shorted a stock and never will.
I seek truth. I don't sugar coat. Real DD does reveal emotion or take sides. It's about facts.
Otiko hides too much.
SCORE! LOL! Otiko has a long history of not revealing key information and giving misleading information.
He should hire a real PR firm and send his brother packing.
100% disagree that I'm not accurate. A provisional sets an early filing date and is useless without the follow-up patent application within a year. That's been my message all along.
I think you have the same message I do except you gave details of benefits Otiko will realize IF and WHEN he files the patent application.
I think the in-between stuff that hasn't happened contributes to the disconnect.
P.S. Some believe Otiko cannot get patent approval for the transdermal patent-pending invention submitted by Applicant Pharmacline.
Otiko should have wrote the caption as follows: "ViaDerma files Provisional Applications with USPTO and Signs LOI with "Insert Real Name," a Canadian Management, Marketing, and Distribution Company.
Using forward looking terms like "Seeks to" falls under the Fluff News definition.
Viabecline is a Phillips Company invention that Otiko has permission to manufacture and distribute. He really needs to stop hiding the fact that he has a non-exclusive license agreement with Phillips until he can prove otherwise.
He misleads by using the words "its" as if Viabecline is Otiko's invention, and by not separating out the words Cannabis Technologies. A reader could believe Otiko actually registered a Cannabis technology with the FDA.
Much better! Time will tell whether he can obtain a patent for a unique delivery system. Hopefully, he will be more careful with his flashy news captions going forward.
Still not accurate. Otiko filed a provisional application with the USPTO. This application does NOT protect an invention he has not presented! He was given a number.
The news release was misleading. Otiko should have said he filed a provisional application. Period. Then he could have stated his intention to file the required follow-up patent application and when he planned to do so.
Otiko has no intellectual property under his name or his company's name beyond the two Trademark applications noted in my section of the iBox.
It is misleading to say the doctor filed a patent application when he announced a provisional application number. These are two distinctly different applications--totally unlike a singular job application.
One cost is low and simply sets a date that disappears without follow-up, and the other cost is very high as it requires a lengthy investigative process. Otiko has to submit unique artwork and technology that doesn't infringe on the Phillips/Keough published application. Once a patent application is approved aka PUBLISHED, it provides protection of an invention.
There are plenty of FAQs and explanations at the site linked below.
U.S. Patent and Trademark Office
Of course I know he has a year. That's why referencing a provisional application as a patent application is highly misleading.
I will continue to correct misleading and false information when I see it.
No patent applications have been submitted by Otiko. Can we get this straight once and for all? A provisional application is NOT a patent application. All Otiko did was submit an inexpensive form that establishes an early filing date that is of benefit ONLY if he files a real patent application within a year.
Yes on dilution. Float grew by ~ 230M in past year. Can confirm in Annual Report this week.
Sure, plenty of reasons, and plenty of opinions, does not equal false statements as you suggested on my part. I believe he chose to be a Pink Sheet biz for a reason.
Do you have any idea how and where he performs clinical trials? Certainly, it can't be in Viaderma's virtual office, or a clinic that treats neuropathy. I doubt he spends much time in Phillips' facility in Oklahoma.
Can it be his home office? How about his movie studio? If it's the foot laser clinic or Coast to Coast Podiatry Clinic on Reseda Boulevard, one might wonder how that can meet any professional standard.
https://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials
Maybe he considers clinical trials performed at Phillips Company to be his own? Sort of like he considers the Phillips/Keough patent-pending delivery system to be his own?
Yep, audited financials would certainly allow us to see the truth behind ViaDerma.